A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Aminolevulinic acid (Primary)
- Indications Glioma
- Focus Diagnostic use
- 14 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 14 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated